2528-31-6

Basic information

• Product Name: L-Glutamic acid, N-[4-[methyl[(phenylmethoxy)carbonyl]amino]benzoyl]-
• CAS NO: 2528-31-6
• Molecular Formula: C21H22N2O7
• Molecular Weight: 414.415
• Mol File: 2528-31-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: L-Glutamic acid, N-[4-[methyl[(phenylmethoxy)carbonyl]amino]benzoyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Glutamic acid, N-[4-[methyl[(phenylmethoxy)carbonyl]amino]benzoyl]-(2528-31-6)
• EPA Substance Registry System: L-Glutamic acid, N-[4-[methyl[(phenylmethoxy)carbonyl]amino]benzoyl]-(2528-31-6)

Safety Data

• Hazardous Substances Data: 2528-31-6(Hazardous Substances Data)

Usage

General Description

L-Glutamic acid, N-[4-[methyl[(phenylmethoxy)carbonyl]amino]benzoyl]- is a compound that contains both L-Glutamic acid and a benzoyl group. L-Glutamic acid is a non-essential amino acid that plays a crucial role in the synthesis of proteins and the regulation of brain function. The benzoyl group consists of a benzene ring attached to a carbonyl group and is commonly used in organic synthesis and as a building block for various pharmaceuticals and agrochemicals. The compound's specific structure suggests that it may have potential applications in drug development or chemical research due to the presence of both L-Glutamic acid and the benzoyl group.

Upstream product

• 2528-30-5 4-<<(benzyloxy)carbonyl>methylamino>benzoic acid 
• 16874-06-9 di-tert-butyl L-glutamate 
• 875667-97-3 (4-azidocarbonyl-phenyl)-methyl-carbamic acid benzyl ester 
• 875667-98-4 di-tert-butyl N-[4-(N-benzyloxycarbonyl-N-methyl)aminobenzoyl]-L-glutamate 

Downstream Products

• 119830-06-7 bis(pivaloyloxymethyl) N-[4-(N-methylamino)benzoyl]-L-glutamate 
• 875668-00-1 bis(pivaloyloxymethyl) N-[4-(N-benzyloxycarbonyl-N-methyl)aminobenzoyl]-L-glutamate 

Relevant articles and documents

Prodrug forms of N-[(4-deoxy-4-amino-10-methyl)pteroyl]glutamate-γ- [ψP(O)(OH)]-glutarate, a potent inhibitor of folylpoly-γ-glutamate synthetase: Synthesis and hydrolytic stability

Ester prodrugs of the phosphinate pseudopeptide N-[(4-deoxy-4-amino-10- methyl)pteroyl]glutamate-γ-[ψP-(O)(OH)]-glutarate (1a) were synthesized. H-phosphinic acids derived from N-Cbz vinyl glycine esters were converted to the desired pseudopeptides by Michael addition to α-methyleneglutarate esters. Pivaloyloxymethyl (POM) ester moieties were incorporated in both the N-terminal and C-terminal fragments prior to formation of either C-P bond, N-Alkylation of the corresponding amides derived from N-(N-methyl)aminobenzoic acid with 2,4-diamino-6-(bromomethyl)pteridine gave the target compounds. POM esters of methotrexate and the corresponding γ-glutamyl conjugate were also synthesized using the same strategy. All prodrugs were evaluated in Chinese hamster ovary cells. Although the pseudopeptide prodrugs were ineffective, prodrugs of methotrexate and the corresponding γ-glutamyl conjugate were equipotent with the parent compounds. Stability of the prodrugs was investigated in both phosphate buffer and cell line medium to provide a rationale for the observed biological data.